This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney function. The goal of this trial is to learn if pegloticase may lower uric acid levels in blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.

Start Date05 Apr 2022

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

EUCTR2021-003176-14-3RD

Phase 4

An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia

Start Date29 Jun 2021

Sponsor / Collaborator

Sanofi-Aventis Groupe SA

100 Clinical Results associated with Rasburicase

100 Translational Medicine associated with Rasburicase

100 Patents (Medical) associated with Rasburicase

491

Literatures (Medical) associated with Rasburicase

07 Dec 2025·Cureus Journal of Medical Science

Tumor Lysis Syndrome Induced by Hormonal Therapy in Metastatic Prostate Cancer: A Case Report

Article

Author: Rodrigues, Carolina ; Machado, Marta ; Mourato, Margarida ; Negrão, Catarina ; Serra, João Tiago

Tumor lysis syndrome (TLS) is a life-threatening oncological emergency resulting from massive cellular destruction. Although most frequently associated with chemotherapy in hematologic malignancies, TLS is uncommon in solid tumors due to their typically slower proliferation rates and treatment response. We report a case of a 67-year-old male with a history of untreated prostate cancer diagnosed two years earlier, who presented with abdominal pain, anorexia, and weight loss. Physical examination revealed painful hepatomegaly. Laboratory tests showed a cholestatic pattern, elevated lactate dehydrogenase, and elevated prostate-specific antigen (PSA) levels. Computed tomography (CT) revealed findings suggestive of pulmonary, hepatic, and adrenal metastases, multiple mediastinal and abdominal lymphadenopathies, and osteolytic bone lesions. Despite the relatively modest increase in PSA levels compared to the extensive disease burden, repeat prostate biopsy confirmed a high-grade prostate adenocarcinoma (Gleason score 9). Hormone therapy with degarelix was initiated. On the third day after treatment initiation, the patient developed both laboratory and clinical features consistent with TLS, including hyperuricemia, hyperphosphatemia, hyperkalemia, and acute kidney injury (Acute Kidney Injury Network (AKIN) stage III). A mediastinal lymph node biopsy obtained via endobronchial ultrasound was subsequently performed but was inconclusive. TLS management was initiated, which included aggressive intravenous hydration, hypouricemic therapy with rasburicase, and correction of electrolyte disturbances. No additional disease-directed therapy, namely, renal replacement therapy, was pursued, given the rapid clinical deterioration, extensive metastatic disease, and absence of feasible oncologic treatment options, with an overall poor prognosis. The patient ultimately died 17 days after the onset of TLS. The literature consistently shows that TLS occurring after initiation of hormonal therapy, including gonadotropin-releasing hormone-axis interventions, is associated with extremely poor outcomes. In all reported treatment-related TLS cases in prostate cancer, mortality was universal despite aggressive supportive management. This case illustrates a rare instance of TLS occurring after initiation of gonadotropin-releasing hormone antagonist therapy in metastatic prostate cancer, highlighting the need for careful risk assessment, close biochemical monitoring, and prompt recognition and management of TLS, especially in patients with high tumor burden.

01 Dec 2025·SUPPORTIVE CARE IN CANCER

Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study

Article

Author: Barnes, Yvonne ; Clark, Christopher ; Drea, Edward ; Gallagher, Jack Ray ; Cairo, Mitchell Stuart ; Carroll, Susan

Abstract:

Purpose:

This retrospective, real-world (RW) study utilizing propensity score matching investigated tumor lysis syndrome (TLS)-related mortalities following anti-hyperuricemic (HU) monotherapy (allopurinol vs. rasburicase) in hematological malignancies. The study aim was to determine if a significant difference exists in the proportion of TLS-associated mortalities in hematological malignancy patients who received either rasburicase or allopurinol.

Methods:

Following random selection of patient cases of rasburicase or allopurinol monotherapy, 141 in each group were PS-matched for TLS risk using 11 predictive covariates.

Results:

Rasburicase-treated patients had significantly lower TLS-associated mortality (2.1% ( n = 3) vs. 7.1% ( n = 10) ( p = 0.047)).

Conclusions:

Following successful PS matching of TLS-risk factors, this study suggests rasburicase statistically significantly reduces TLS-associated mortalities compared to allopurinol.

01 Dec 2025·AMERICAN JOURNAL OF EMERGENCY MEDICINE

High risk and low incidence diseases: Tumor lysis syndrome

Review

Author: Beck-Esmay, Jennifer ; Koyfman, Alex ; Long, Brit ; Molyneux, Kevin

INTRODUCTION:

Tumor lysis syndrome (TLS) is a serious condition that carries with it a high rate of morbidity and mortality.

OBJECTIVE:

This review highlights the pearls and pitfalls of TLS, including presentation, diagnosis, and management in the emergency department (ED) based on current evidence.

DISCUSSION:

TLS is a potentially deadly metabolic oncologic emergency. It most commonly occurs in patients with acute leukemia and lymphoma undergoing chemotherapy, but it may also occur in those with solid tumors and in those undergoing treatment with immune checkpoint inhibitors. Diagnosis requires clinical suspicion, thorough history and physical examination, laboratory testing, and electrocardiogram. The diagnosis is based on the Cairo-Bishop classification. Patients present with a variety of complications such as electrolyte abnormalities, renal injury, arrhythmias, respiratory failure, and neurological abnormalities such as seizures. ED treatment includes fluid resuscitation, managing electrolyte abnormalities, catalyzing uric acid oxidation with rasburicase, and excluding other life-threatening conditions. Hemodialysis may be necessary.

CONCLUSION:

An understanding of TLS can assist emergency clinicians in diagnosing and managing this potentially deadly disease.

News (Medical) associated with Rasburicase

09 Sep 2025

·www.einpresswire.com

Harm from delayed administration of rasburicase for tumour lysis syndrome

This national patient safety alert has been issued by the NHS England National Patient Safety team. It instructs all organisations providing emergency departments and cancer services to take steps to reduce the risk of harm from delayed administration of rasburicase for tumour lysis syndrome (TLS). All actions should be completed by 9 March 2026. The issuing of this alert coincides with the publication of new British Society for Haematology guidelines on TLS management . About this alert TLS is a life-threatening emergency that can develop when cancer cells break down rapidly, releasing harmful substances into the bloodstream. It requires urgent treatment with rasburicase in high-risk cases, ideally within 1 hour. Patients are at risk of TLS when they have blood cancers with high tumour burden or fast-growing malignancies, particularly when starting cancer treatment that rapidly destroys cancer cells. The release of harmful cellular contents into the blood stream can overwhelm the body’s normal clearance mechanisms and lead to kidney failure, heart rhythm problems, seizures, and even death. Rasburicase is a time-critical medication that rapidly converts uric acid released from dying cancer cells into more soluble compounds that can be safely eliminated. The alert requires NHS organisations providing emergency departments and cancer services to implement specific improvements within 6 months, including updated risk assessment protocols, ensuring medication availability, and addressing operational barriers to timely treatment. About national patient safety alerts This alert has been issued as a national patient safety alert. The NHS England National Patient Safety team was the first national body to be accredited to issue national patient safety alerts by the National Patient Safety Alerting Committee (NaPSAC) . All national patient safety alerts are required to meet NaPSAC’s thresholds and standards . These thresholds and standards include working with patients, frontline staff and experts to ensure alerts provide clear, effective actions for safety-critical issues. NaPSAC requires providers to introduce new systems for planning and coordinating the actions required by any national patient safety alert across their organisation, with executive oversight. Failure to take the actions required under any national patient safety alert may lead to the Care Quality Commission taking regulatory action. Patient safety alerts are shared rapidly with healthcare providers via the Central Alerting System (CAS) . Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

11 Dec 2024

·www.globenewswire.com

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy • Prelude plans to seek a partner for future development of PRT2527 in hematologic malignancies WILMINGTON, Del., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly selective CDK9 inhibitor, as monotherapy and in combination with zanubrutinib in patients with relapsed/refractory lymphoid malignancies. The data were presented at a poster session of the 66th American Society of Hematology Annual Meeting in San Diego, California. The study investigators reported on the 46 patients that were enrolled, treated, and safety evaluable as of September 17, 2024. PRT2527 was generally well-tolerated through 4 dosing cohorts as monotherapy and 3 dosing cohorts in combination with zanubrutinib. PRT2527 monotherapy and in combination with zanubrutinib demonstrated an acceptable safety profile with evidence of preliminary activity in patients with relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy. “CDK9 has long been considered a potential therapeutic approach for treating hematologic malignancies and a highly selective CDK9 inhibitor was sought to minimize off target toxicity,” stated Jane Huang, M.D., President and Chief Medical Officer of Prelude. “We are encouraged by the results demonstrated to date by PRT2527 both as a monotherapy and particularly in combination with zanubrutinib resulting in an overall response rate of 38.5% including two patients with aggressive lymphomas who had received prior CAR-T therapy. These results represent a positive step for CDK9 inhibition as a possible future therapeutic approach for patients with aggressive hematologic cancers with limited treatment options.” PRT2527 Interim Phase 1 ResultsPRT2527 is an investigational, potent and highly selective CDK9 inhibitor being evaluated in select relapsed/refractory (R/R) hematologic malignancies as monotherapy and in combination with zanubrutinib. As of the cutoff date, 46 patients with relapsed/refractory lymphoid malignancies were treated with PRT2527. 29 patients were treated once weekly via intravenous infusion at four dose levels of PRT2527 monotherapy (9 mg/m2, 15 mg/m2, 18 mg/m2, 24 mg/m2) and 17 patients were treated once weekly at three dose levels of PRT2527 (9 mg/m2, 15 mg/m2, 18 mg/m2) in combination with zanubrutinib administered orally starting on C1D1 at 320 mg daily or 160 mg BID. Initial Safety DataThe most frequent treatment emergent adverse events (TEAEs) observed in ≥20% of patients were neutropenia (48%) and nausea (33%), and the most frequent grade ≥3 TEAEs (≥10% of patients) were neutropenia (46%) and anemia (11%). Five patients discontinued treatment due to TEAEs in the monotherapy cohort; 3 TEAEs in 1 patient were treatment related: grade 3 hypotension, grade 3 diarrhea, and grade 4 neutropenia (n=1 each). No TEAEs led to treatment discontinuation in the combination therapy cohort. PRT2527 dose interruptions due to TEAEs occurred in 17 patients (11 monotherapy; 6 combination therapy). Most dose interruptions were due to neutropenia and were managed with growth factor support. One DLT of grade 3 tumor lysis syndrome (TLS) occurred in a patient with primary cutaneous peripheral T cell lymphoma who had extensive disease at the 24 mg/m2 monotherapy dose level and did not receive ramp-up dosing. TLS was managed with rasburicase and IV fluids and resolved. The patient was able to resume study treatment as planned. No DLTs were observed in the combination therapy cohort. Dose level 3 (18 mg/m2) was selected for dose confirmation for monotherapy and in combination with zanubrutinib due to higher rates of grade 3/4 neutropenia and of dose interruptions and reductions in the 24 mg/m2 dose level. Analysis of Initial Clinical ActivityOf the 23 efficacy evaluable patients in the monotherapy cohort, complete responses (CRs) were observed in 1 patient (DLBCL) and 3 partial responses observed (TCL), with an overall response rate (ORR) of 17.4% (4 of 23). Of the 13 patients in the combination cohort who were evaluable for efficacy, complete responses (CRs) were observed in 3 patients (2 DLBCL, 1 MCL) and 2 partial responses (PRs) observed (DLBCL and CLL) with an overall response rate (ORR) of 38.5% (5 of 13). The above-noted presentation can be found at Publications - Prelude Therapeutics (preludetx.com). “We believe the clinical data presented today with PRT2527 confirm our hypothesis that a highly selective and potent inhibitor of CDK9 has the potential to offer meaningful clinical activity for patients with hematologic malignancies, while avoiding the off-target toxicities observed with less selective agents,” stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. “However, given the significant progress and potential of our SMARCA degrader programs that are currently advancing in the clinic, along with our productive discovery organization, we plan to focus our resources towards the continued advancement of those programs. As a result, we will only advance the CDK9 program with a partner beyond completion of the current ongoing Phase 1 study.” About Prelude Therapeutics Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates, the potential safety, efficacy, benefits and addressable market for Prelude’s product candidates, and clinical trial results for Prelude’s product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.  Investor Contact: Robert A. Doody Jr.Senior Vice President, Investor Relations 484.639.7235rdoody@preludetx.com

Clinical ResultPhase 1ASHCell TherapyImmunotherapy

24 Aug 2023

·www.globenewswire.com

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

DOYLESTOWN, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it has appointed Dr. Jean-Pierre Bizzari to its Board of Directors and is naming Dr. Richard Peters as its new Chairman of the Board. Dr. Bizzari will replace Mr. Christian Schade, who is stepping down from the Board. “We warmly welcome Dr. Jean-Pierre Bizzari to our Board of Directors. Jean-Pierre is an esteemed industry thought leader and was the Group Head Clinical Development Oncology at Celgene where he was responsible for developing some of the most significant and successful oncology therapeutics,” said Dr. Oren Gilad, President and Chief Executive Officer of Aprea. “Jean-Pierre joins our Board as Chris Schade retires from his role as Chairman and member of the Board to focus on his other commitments. Dr. Richard Peters has served as independent Director of Aprea since June 2020 and Chair of the Compensation Committee since November 2020. Dr. Peters will now also assume the role of Chairman, and we welcome his leadership as he guides our diverse and experienced Board.” Dr. Jean-Pierre Bizzari joins the Aprea Board having led a remarkable and distinguished career in oncology. He has been responsible for numerous global approvals of several billion-dollar therapies, including: Fotomustine, Taxotere, Revlimid, Abraxane, Vidaza, PTCL, Eloxatin, CPT-11, Gliadel, Rasburicase, and Pomalidomide to name a few. He has been involved in acquisition and licensing agreements with several major pharmaceutical companies. Dr. Bizzari is a member and leader on many scientific committees and is currently a member of the Scientific Advisory Board for the National Cancer Institute in France; a Board member of the European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the EORTC New Drug Advisory Committee. He currently is on the Boards of Halozyme, ADC Therapeutics, NETRIS Pharma, and Oxford BioTherapeutics. Most recently, Dr. Bizzari was the Group Head Clinical Development Oncology at Celgene. He led global clinical development conducting over 25 Phase 3 trials, was responsible for global operations of over 950 people and was chairman of the Hematology Oncology development committee. Prior to Celgene, Dr. Bizzari was the VP of clinical development oncology at Sanofi-Aventis where he was responsible for the worldwide clinical development and approvals. He also served as VP of clinical development oncology at Rhone-Poulenc Rorer where he shepherded a deep pipeline of oncology candidates. Dr. Bizzari holds a degree in mathematics, and completed his medical studies in Nice, France. He completed his residency in oncology at Pitie Salpetriere Hospital in Paris. Dr. Bizzari said, “I am excited to join this dedicated Board, and look forward to contributing to the success of their very promising therapeutics at the center of synthetic lethality and DNA Damage Repair drug development.” Mr. Christian Schade noted, “It has been an honor to serve on this dynamic Board. I leave knowing that the Board and Company are in good hands, and that everyone involved is committed to realizing the tremendous potential of this company.” Dr. Richard Peters added, “I thank Chris for his years of service to the Board and astute leadership as we successfully navigated the company through several challenges. I look forward to working closely with our Board and terrific management team as we move towards several meaningful Company milestones.” About ApreaAprea Therapeutics, Inc. is a clinical stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. Our WEE1 inhibitor is being advanced to IND submission. For more information, please visit the company website at www.aprea.com. The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Forward-Looking Statement Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are submits to risks and uncertainties including, without limitation, risks related to the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials, futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results )including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statement for any reason, except as required by law. Investor Contact: Mike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com

Executive ChangePhase 3

100 Deals associated with Rasburicase

External Link

KEGG	Wiki	ATC	Drug Bank
D05704	Rasburicase	V03AF07	DB00049

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperuricemia	European Union	Sanofi Winthrop Industrie SA	23 Feb 2001
Hyperuricemia	Iceland	Sanofi Winthrop Industrie SA	23 Feb 2001
Hyperuricemia	Liechtenstein	Sanofi Winthrop Industrie SA	23 Feb 2001
Hyperuricemia	Norway	Sanofi Winthrop Industrie SA	23 Feb 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	Phase 3	China	Sanofi	01 Oct 2007
Hematologic Neoplasms	Phase 3	China	Sanofi	01 Oct 2007
Non-Hodgkin Lymphoma	Phase 3	China	Sanofi	01 Oct 2007
Leukemia	Phase 3	United States	Sanofi	01 Apr 2004
Lymphoma	Phase 3	United States	Sanofi	01 Apr 2004
Malignant Solid Neoplasm	Phase 3	United States	Sanofi	01 Apr 2004
Tumor Lysis Syndrome	Phase 3	United States	Sanofi	01 Apr 2004
Acute Myeloid Leukemia	Phase 2	United States	Sanofi	01 Jan 2008
Blast Phase Chronic Granulocytic Leukemia	Phase 2	United States	Sanofi	01 Jan 2008
Chronic phase chronic myeloid leukemia	Phase 2	United States	Sanofi	01 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2023	Not Applicable	Neoplasms	715	Rasburicase	dajlfmnhec(vleyaxejfg) = jyqrddjgwp jfdmwamstu (dowqbpvohe ) View more	-	23 Oct 2023
				Allopurinol	dajlfmnhec(vleyaxejfg) = dennjquuek jfdmwamstu (dowqbpvohe ) View more
EULAR2022	Not Applicable	Arthritis, Gouty	17	Rasburicase 1.5mg/d	mjqlabvrtv(riwbyuooae) = nnndbgjyli kvajyzydli (aemkiqujjm ) View more	-	01 Jun 2022
EHA2020	Not Applicable	Tumor Lysis Syndrome \| Leukemia \| Lymphoma	55	Low dose Rasburicase	ktwdypwjda(eubmtgumyx) = ldfzbzmnap tomqnmnema (mfyaosyxfh )	Positive	14 May 2020
NCT01200485 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Tumor Lysis Syndrome \| Leukemia ... View more	55	Rasburicase (Arm A (Rasburicase))	dpbqjagkci = ekkpeykjyn sdnwhiphjo (qflylffgmq, bhacqrgpoy - hrzskdsdio) View more	-	31 Jan 2020
				Allopurinol (Arm B (Allopurinol))	dpbqjagkci = gvdctrhoru sdnwhiphjo (qflylffgmq, fztwajvvph - aqczqzavvo) View more
EHA2019	Not Applicable	Hematologic Neoplasms	-	Low dose rasburicase	qlmpcguinu(wbdhbhmeqj) = hdlcshdosj kshomsskgt (hqbylocumr ) View more	-	16 May 2019
NCT01564277 (CTgov)	Phase 2	Recurrent Adult Acute Lymphoblastic Leukemia \| Adult acute myeloid leukemia with del(5q) \| Burkitt Lymphoma ... View more	24	rasburicase+allopurinol (Arm I (1.5mg Rasburicase))	clgcbyhohz = hzfkblynav gilcpgcwop (chirejlvmk, ebefqxwsid - wfnxtmbhfd) View more	-	08 Dec 2017
				rasburicase+allopurinol (Arm II (3 mg Rasburicase))	clgcbyhohz = mmbxvjsulq gilcpgcwop (chirejlvmk, zpfeguqlez - bvpyclldhr) View more
NCT00513474 (CTgov)	Phase 1	Multiple Myeloma \| Myelodysplastic-Myeloproliferative Diseases \| Myeloproliferative Disorders ... View more	46	allogeneic hematopoietic stem cell transplantation+cyclosporin-A+etoposide+rasburicase+busulfan+fludarabine+cyclophosphamide+Tacrolimus+sirolimus+methotrexate (Rasburicase Group)	bcdwekvcgc = ygzqjjmjcp lrchkkgedh (sqhxhtxnup, dolxpbzejg - eojcufgspw) View more	-	11 Apr 2017
				allogeneic hematopoietic stem cell transplantation+cyclosporin-A+etoposide+busulfan+fludarabine+cyclophosphamide+Tacrolimus+sirolimus+allopurinol+methotrexate (Control Group)	bcdwekvcgc = bseeqzgpxd lrchkkgedh (sqhxhtxnup, qhjozttjyb - uvocuzpauv) View more
NCT00628628 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Chronic phase chronic myeloid leukemia \| Tumor Lysis Syndrome ... View more	82	Rasburicase (Group A: Single Dose)	zdndbnzeas = vhnoxtyfve toyhofgzlv (wphwwefspe, ykjnadoyvn - wotkiexpnc) View more	-	01 Aug 2013
				Rasburicase (Group B: Daily Dose)	zdndbnzeas = ipsmitjsoj toyhofgzlv (wphwwefspe, hjmtcsjrtv - cuzvbzzymr) View more
NCT00756964 (RasbAKI, CTgov)	Phase 2	Hyperuricemia \| Acute Kidney Injury	26	Rasburicase (Rasburicase Group)	srxcreuige = bxpfceujmx qawkwbxwwu (ktmppfkqdt, wpztqkcuwg - ybkyioxmtg) View more	-	03 Sep 2012
				Placebo (Placebo Group)	srxcreuige = nfawtmwgbb qawkwbxwwu (ktmppfkqdt, xreupcmumu - jtskgkmxly) View more
NCT00628628 (Pubmed \| Ann Oncol)	Phase 2	Tumor Lysis Syndrome	82	Single-dose rasburicase	tzgehanatw(syrvpgnahe) = one patient with glucose-6-phosphate dehydrogenase deficiency developed methemoglobinemia and hemolysis eapadfeehp (fqejcbyzlt )	-	01 Jun 2012
				Daily dosing for 5 days

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis